Submission of Financial Results for the quarter ended June 30, 2026.

.[STT.L IJTBOB^ETOSIES LIMITE,D CIN: L74l20UPl99JpLCOt5605 Regd. OIIice: Orlice No. 87. A-40, Sector 4, Noida, Cautam Buddha Nagar, Uttar pradesh 201301 Corporate Orlice: House No 4-50 t Sy No lJ4 1f,2 Btock B 8th Floor Flat No g0l. The platina Asta I La bo rato r ies L imited K0ndapur Road, Gachibowli, KV.Rangareddy, Seri Lingampally, 'I elangana, lndia,50fi)32 SCRIP CODE:512600, SECURITY lD: ASTALLTD, BSE hdia Email: meill00@redilTmail.com: Mob. No:63027J097.1, Website: https://astallabs.com/ Date:14-08-2026 The Deputy Manager (Department of Corporate Services) BSE Limited P, J. Towers Dalal Street, Fort, Mumbai- 400001 Sub: Unaudited Standalone and Consolidated Financial Results for the quarter ended 30rh rune, 2026 pursuant to Regulat;on 33 of the sEBt (Listing Obligations and Disclosure Requirements) Regulations, 2015 Ref.: Scrip Code: 512600 ld: ASTALLTD Respected Sir/ Madam, Pursuant to the Regulation 33 of Securities and Exchange Board of lndia (Listing Obligation and Disclosure Requirements) Regulation, 2015 (Listing Regulations), the Board of Directors at their meeting held on 14th August, 2026 have considered and approved, the Unaudited Standalone and Consolidated Financial Results of the company for the quarter ended 30th lune, 2026 along with the limited review report of the auditors thereon. The Auditors' Limited Review Report on the said financial results is also attached herewith. The Board Meeting commenced at 05:00 p.m. (lST) and concluded at 05:38 p.m. (tST) The aforesaid information is also available on the website of the Company https://astallabs.com. We request you to take the aforesaid information on record for dissemination through your website. Thanking you, Yours Faithfully, For Astal Laboratories /n.Lr^1.1 Kumar Mahendra \O> (Company Secretary & Membership No.: A71224 SATIIUTUBI & CHARTERED ACCOUNTANTS INDIA Limited Review Report on Standalone Unaudited Quarterly Financial Results of Astal Laboratories Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 20L5 Board of Directors Astal Laboratories Limited We have reviewed the accompanying statement of Standalone unaudited quarterly financial results of Astal Laboratories Limited for the quarter ended on 30tr June, 2026, attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations & Disclosure Requirements) Regulation,20L5, (the Regulation) as amended, (the "Listing Regulations'). This statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accouniing Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued ttrereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review. We have conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly- we do not express an audit opinion. Page L of 2 Off: 11 -13-137712, Flat No. 401, City Centre Complex, Margadarshi Colony, Kothapet, Hyderabad-500035. Ph: 9391 686797 Email: casathuluri93@gmail.com Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards and other recognized accounting practices and policies has not disclor"d tfru information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligationr and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement. For Sathuluri & Co Chartered Accountants KFirm RI"g No.006383S S.S.P Parbr M.No.2027'1.0 UDIN : 26202710FOVAKA5300 Place: Hyderabad Date: 14-08-2026 Page 2 of 2 frSTAL IJIBOS.ITOSIES IJIIITf,I' CIN: L74l2OUPl 99JpLC0l5605 Regd. Office: Office No,87, A-40, Sector 4, Noida, Gautam Buddhr Nagar, Uttar pradesh 201301 Corporate OIIice: House No 4-50 I Sy No tJ4 IJ2 Btock B 8th Fl;r Ftat No 801. The ptrti,, Aslal Labo ratories Limited Kondapur Road, Gachibowli, K.V.Rangarcddy, Seri Lingampally, Telangana, India,5000J2 SCRIP CODO: 512600, Sf,CURITy tD: ASTALLTD. BSE India Email: meill00@rediffmail.com: Mob. No:630273097j, \yebsite: https://astallabs.com/ Statement of Standalone Unaudited Financial Results for the quarter ended 3Oth June, 2O2E 'Rs. ln Lakhs S. No. Particulars Year to Corsponding Date Preceding 3 Months 3 Months Figures for 3 Months Ended in Ended Current ended Previous Period Year Ended 30.06.2025 31.03.2025 30.06.2025 31.03.2025 (Unaudited) (Audited) (Unaudited) (Audited) 1 Revenue a) From operations 3,95t.47 4,09L.70 2,532.66 15,599.53 b) Other lncome 3.27 6.63 5.61 19.1.6 Total Revenue 3,954.62 4,098.32 2,5t8.27 15,518.68 2 Expenses (a) Cost of Material Consumed 4,087.52 3,622.87 2,308.22 1,5,288.45 (b) Purchases of stock-in-trade (c) Change in inventories of finished goods, work-in-progress and stock-in- trade (799.s0) 722.72 (161.63) (1,401.s6) (d) Em ployees Benefits expenses 61-.82 80.72 44.72 2L1..26 (e) Fina nce Cost 32.79 46,t2 30.08 140.91 (f) Depreciation amortization expenses 17.74 32.L0 72.OL 68.84 (e) Other Expenses 64.60 46.O2 25.59 224.23 Total Expenses 3,458.97 3,951.14 2,258.98 L4,532.L2 3 Profit from ordinary activities before exceptonal ltems (1 - 2) 495.65 t47 .78 279.29 1,085.s5 4 Exceptional ltems - lncome/ (Expensesl 5 Profit from ordinary activities before tax (3 - 4) 495.65 747 .t8 279.29 1,085.56 5 Tax Expenses (a) Current Tax 103.13 47.73 45.6L 258.84 (b) Deferred Tax 21.83 -3.14 24.77 16.17 7 Profit/(loss) ,or the period ( 5 -6) 370.69 108.59 208.96 811.55 8 A (i) ltems that will not be reclassified to profit or loss (net of tax) (ii) lncome Tax relating to items that will not be reclassified to profit or loss B (i) ltems that will not be reclassified to profit or loss (net of tax) (ii) lncome Tax relating to items that will not be reclassified to profit or loss /97 \C .T.STTL IJIBOE.f,TOEIES UMIIED CIN: L74 I 20Upl 993pLC0r5605 Regd. Olfice: Omce No. 87, A-40, Sector,l, Noida, Gautam Buddha Nagar, Uttar pradesh 201301 Corporate OIIice: House No 4-50 I Sy No lJ4 tJ2 Btock B 8th Fto; Ftar No 801, The phtina Astal Laboratories Limitcd Kondapur Road, Gachibowti, K-V-Rangareddy, Seri Lingampally, Telangana, India,5000j2 SCRtp CODE: 512600, SICURITY ID: ASTALLTD. BSE India Email: meill00@rediffmril.com: Mob. No:6J0273097J, Website: https://astallabs.com/ 9 Total Comprehensive lncome, net of tax (7 + 8) 370.69 108.59 208.96 811.5 5 10 Paid up equity share capital (Face 1/alue of Rs.10/- each) 4379.89 4223.L2 984.56 4223.t2 11 Earning per share (of Rs.10/-each) not annualised (a) Basic 0.861 0.288 2.L26 4.757 (b) Diluted 0.857 0.275 L.737 4.310 Notes: I The above Unaudited Standalone Financial Results of the company for the quarter ended June 30, 2026 have been reviewed by the Audit Committee and have been approved by the Board of Directors at its meeting held on 14r1, August, 2026. ,) TheCompanyhasonlyonebusinessSegment'Manufa"t,,ing@ Pharmaceutical lngredients (Bulk Drugs). 3 Figures in respect of the previous year/period have been ."ur.anged /.egrorped *hoelrer [Showing first 8,000 characters — download PDF for full document]